Traders should monitor the upcoming BLA submission in H1 2026 and potential Priority Review as key catalysts; while fundamentals remain weak due to losses, the extended cash runway reduces near-term dilution risk and supports execution through potential approval.
Price Chart
Executive Summary
DBV Technologies reported full-year 2025 financial results, showing increased R&D spending due to pre-commercial inventory and clinical trial costs, leading to a wider net loss of $147.0 million. However, the company significantly strengthened its balance sheet, ending 2025 with $194.2 million in cash and securing an additional $94 million in January 2026, extending its cash runway into Q2 2027. The progress in clinical development, including positive Phase 3 VITESSE trial results and upcoming BLA submissions for its VIASKIN® Peanut Patch, positions the company for potential regulatory approval and commercialization.
Key Financial Metrics
Key Facts
- Net loss increased to $147.0 million in 2025 from $113.9 million in 2024
- Cash and cash equivalents totaled $194.2 million as of December 31, 2025, up from $32.5 million in 2024
- Additional $94 million in gross proceeds received in January 2026 from warrant exercises
- Positive topline results from Phase 3 VITESSE trial in children aged 4–7 years
- BLA submission for 4–7 year olds expected in first half of 2026, with potential Priority Review
- R&D expenses rose by $27.3 million, driven by $16.1 million in pre-commercial inventory and ongoing clinical costs
Financial Impact
Net loss expanded by $33.1 million YoY, but cash position improved by $161.7 million net of operating outflows due to financing activities
Risk Factors
- Continued net losses and reliance on future financing if development timelines extend
- Regulatory risk around BLA approval, especially given prior FDA rejections of the VIASKIN® Peanut Patch
- High cash burn — net $121.2 million used in operations in 2025 — which could accelerate under commercialization
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3263464 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 29, 2026 27d ago | 8-K | $11.76 $9.77 | ▼ −16.92% | ▼ −18.83% | $9.98 (−15.14%) |
Jul 27, 2026 13w ago | S-3ASR | $13.90 $13.50 | ▲ +2.88% | ▲ +3.95% | $9.98 (+28.20%) |
Jul 6, 2026 16w ago | Press Release | $17.35 $15.92 | ▼ −8.24% | ▼ −8.79% | $9.98 (−42.48%) |
Jun 29, 2026 17w ago | 8-K | $16.40 $15.61 | ▼ −4.82% | ▼ −5.42% | $9.98 (−39.15%) |
Apr 30, 2026 25w ago | Press Release | $19.87 $19.73 | ▼ −0.70% | ▼ −3.05% | $9.98 (−49.77%) |
Mar 26, 2026 30w ago | Press Release | $20.00 $20.36 | ▲ +1.80% | ▼ −2.06% | $9.98 (−50.10%) |
Mar 26, 2026 30w ago | Press Release | $20.00 $20.36 | ▲ +1.80% | ▼ −2.06% | $9.98 (−50.10%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers